Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 82
Filtrar
1.
J Cardiovasc Med (Hagerstown) ; 25(2): 158-164, 2024 02 01.
Artigo em Inglês | MEDLINE | ID: mdl-38149702

RESUMO

AIMS: There is wide variability in the practice of cardiac preservation for heart transplantation. Prior reports suggest that the type of solution may be linked with a reduced incidence of posttransplantation complications. METHODS: Adult (≥18 years old) heart recipients who underwent transplantation between 2015 and 2021 in the United States were examined. Recipients were stratified by solution utilized for their grafts at the time of recovery: University of Wisconsin, histidine-tryptophan-ketoglutarate (HTK), or Celsior solution. The primary endpoint was a composite of 30-day mortality, primary graft dysfunction, or re-transplantation. Risk adjustment was performed for the recipient, donor, and procedural characteristics using regression modeling. RESULTS: Among 16 884 recipients, the group distribution was University of Wisconsin solution 53%, HTK 22%, Celsior solution 15%, and other 10%. The observed incidence of the composite endpoint (University of Wisconsin solution = 3.6%, HTK = 4.0%, Celsior solution = 3.7%, P = 0.301) and 1-year survival (University of Wisconsin solution = 91.7%, HTK = 91.3%, Celsior solution = 91.7%, log-rank P = 0.777) were similar between groups. After adjustment, HTK was associated with a higher risk of the composite endpoint [odds ratio (OR) 1.249, 95% confidence interval (CI) 1.019-1.525, P = 0.030] in reference to University of Wisconsin solution. This association was substantially increased among recipients with ischemic periods of greater than 4 h (OR 1.817, 95% CI 1.188-2.730, P = 0.005). The risks were similar between University of Wisconsin solution and Celsior solution (P = 0.454). CONCLUSION: The use of the histidine-tryptophan-ketoglutarate solution during cold static storage for cardiac preservation is associated with increased rates of early mortality or primary graft dysfunction. Clinician discretion should guide its use, especially when prolonged ischemic times (>4 h) are anticipated.


Assuntos
Transplante de Coração , Soluções para Preservação de Órgãos , Disfunção Primária do Enxerto , Adulto , Humanos , Adolescente , Preservação de Órgãos/efeitos adversos , Disfunção Primária do Enxerto/etiologia , Disfunção Primária do Enxerto/prevenção & controle , Soluções para Preservação de Órgãos/efeitos adversos , Transplante de Coração/efeitos adversos , Insulina , Glucose/efeitos adversos
2.
Biomed Pharmacother ; 143: 112237, 2021 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-34649361

RESUMO

Intestinal transplantation has become an established therapeutic option that provides improved quality of life to patients with end-stage intestinal failure when total parenteral nutrition fails. Whereas this challenging life-saving intervention has shown exceptional growth over the past decade, illustrating the evolution of this complex and technical procedure from its preclinical origin in the mid-20th century to become a routine clinical practice today with several recent innovations, its success is hampered by multiple hurdles including technical challenges such as surgical manipulation during intestinal graft procurement, graft preservation and reperfusion damage, resulting in poor graft quality, graft rejection, post-operative infectious complications, and ultimately negatively impacting long-term recipient survival. Therefore, strategies to improve current intestinal transplantation protocol may have a significant impact on post-transplant outcomes. Carbon monoxide (CO), previously considered solely as a toxic gas, has recently been shown to be a physiological signaling molecule at low physiological concentrations with therapeutic potentials that could overcome some of the challenges in intestinal transplantation. This review discusses recent knowledge about CO in intestinal transplantation, the underlying molecular mechanisms of protection during intestinal graft procurement, preservation, transplantation and post-transplant periods. A section of the review also discusses clinical translation of CO and its challenges in the field of solid organ transplantation.


Assuntos
Monóxido de Carbono/uso terapêutico , Isquemia Fria , Intestinos/transplante , Soluções para Preservação de Órgãos/uso terapêutico , Transplante de Órgãos , Traumatismo por Reperfusão/prevenção & controle , Preservação de Tecido , Animais , Monóxido de Carbono/efeitos adversos , Monóxido de Carbono/metabolismo , Isquemia Fria/efeitos adversos , Difusão de Inovações , Sobrevivência de Enxerto , Humanos , Intestinos/metabolismo , Intestinos/patologia , Soluções para Preservação de Órgãos/efeitos adversos , Soluções para Preservação de Órgãos/metabolismo , Transplante de Órgãos/efeitos adversos , Segurança do Paciente , Traumatismo por Reperfusão/etiologia , Traumatismo por Reperfusão/metabolismo , Traumatismo por Reperfusão/patologia , Medição de Risco , Fatores de Risco , Resultado do Tratamento
3.
Exp Clin Transplant ; 19(8): 842-848, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-34142940

RESUMO

OBJECTIVES: Histidine-tryptophan-ketoglutarate and University of Wisconsin solutions are currently used for pancreas graft preservation. Our hypothesis was whether the use of histidine-tryptophan-ketoglutarate solution is associated with worse pancreas graft survival than University of Wisconsin solution, in general and after prolonged cold ischemic time of ≥12 hours. MATERIALS AND METHODS: This retrospective study investigated the impact of static cold storage in histidine-tryptophan-ketoglutarate (n = 133) versus University of Wisconsin (n = 107) solution on outcomes of 240 pancreas transplant procedures. Patient and graft survival rates were compared after 1, 3, and 5 years in both groups. Serum lipase, amylase, and C-reactive protein levels and incidence of surgical complications were evaluated at postoperative week 1. A subgroup analysis of 96 grafts (52 with histidine-tryptophanketoglutarate/44 with University of Wisconsin) with pancreas graft cold ischemic time ≥12 hours was also performed. RESULTS: At mean follow-up of 75.2 ± 9.9 months, both groups demonstrated comparable short- and long-term patient survival. Overall, pancreas graft survival was slightly better in the histidine-tryptophan-ketoglutarate group (Kaplan-Meier analysis, log-rank P = .013). However, the subgroup analysis of grafts with cold ischemic time ≥12 hours showed slightly better pancreatic graft survival in the University of Wisconsin group, although not significantly (log-rank P = .95). Serum lipase and C-reactive protein levels at postoperative week 1 were higher in the histidinetryptophan-ketoglutarate group. Surgical complications were comparable. Multivariable Cox regression analysis identified neither solution as a risk factor affecting patient and graft survival. CONCLUSIONS: Although a direct comparison between histidine-tryptophan-ketoglutarate and University of Wisconsin showed better pancreas graft survival with histidine-tryptophan-ketoglutarate, the multivariable analysis showed that the perfusion solution does not significantly influence patient and graft survival. However, in the analysis of transplants with cold ischemic time ≥12 hours, pancreas graft survival was slightly better in the University of Wisconsin group, although not significantly.


Assuntos
Histidina , Soluções para Preservação de Órgãos , Adenosina , Alopurinol/efeitos adversos , Proteína C-Reativa , Isquemia Fria/efeitos adversos , Glucose/efeitos adversos , Glutationa , Humanos , Insulina/efeitos adversos , Lipase , Soluções para Preservação de Órgãos/efeitos adversos , Pâncreas , Rafinose/efeitos adversos , Estudos Retrospectivos , Resultado do Tratamento , Triptofano , Universidades , Wisconsin
4.
Exp Clin Transplant ; 19(6): 511-521, 2021 06.
Artigo em Inglês | MEDLINE | ID: mdl-33797354

RESUMO

OBJECTIVES: Renal transplant with ABO-incompatible donors expands the donor pool. Earlier studies have focused the use of protocol biopsies in ABOincompatible transplant patients. Our study described outcomes of indication (for cause) renal biopsies and clinical outcomes in patients with ABO-incompatible renal transplant. MATERIALS AND METHODS: This retrospective study included 164 patients from January 2012 to June 2019. Biochemical parameters, serial immunoglobulin G anti-ABO titers, and class I and II donor-specific antibody findings were obtained from hospital records, and renal graft biopsies were reviewed according to the Banff 2017 update. RESULTS: We analyzed the results of 65 biopsies from 54 patients. Biopsy-proven acute antibody-mediated rejection (12.8%) was found to be more prevalent than acute cellular rejection (1.8%). Patients with antibodymediated rejection all had microvascular inflammation (g+ptc score of 2 or more, where g+ptc is the sum of the glomerulitis and peritubular capillaritis scores) and were positive for C4d. Acute tubular injury per se was seen in 10.3% of patients; 65% of these patients had C4d positivity in peritubular capillaries, and only 1 patient developed chronic active antibody-mediated rejection on follow-up. Patient and death-censored graft survival rates were 92% and 98% at 1 year after transplant and 88% and 91% at 3 years, respectively. Patients with an episode of antibody-mediated rejection had lower rates of patient (76.5%) and deathcensored graft survival (84.6%) at 1 year. CONCLUSIONS: The microvascular inflammation score (g+ptc score of 2 or higher) is more reliable than diffuse C4d positivity to determine antibody-mediated rejection in ABO-incompatible transplants because diffuse C4d positivity may also be seen in etiologies unrelated to antibody-mediated rejection. Acute tubular injury with C4d positivity without microvascular injury does not confirm antibody-mediated rejection. We suggest that Banff classification be updated in ABOincompatible transplants to include diagnostic criteria for the diagnosis of antibody-mediated rejection.


Assuntos
Soluções para Preservação de Órgãos , Biópsia , Complemento C4b , Feminino , Rejeição de Enxerto , Humanos , Inflamação , Masculino , Soluções para Preservação de Órgãos/efeitos adversos , Fragmentos de Peptídeos , Estudos Retrospectivos , Resultado do Tratamento
5.
J Vasc Surg ; 74(3): 972-978, 2021 09.
Artigo em Inglês | MEDLINE | ID: mdl-33684476

RESUMO

BACKGROUND: In Canada, tissue distribution is managed by provincial entities. In 2014, Hema-Quebec established a cryopreserved vascular tissue bank accessible to all Canadian hospitals. The objectives of this report were to review the first 5 years of activity of Hema-Quebec's vascular bank and to briefly assess the competitiveness of its products. METHODS: Deceased donors, ages 15 to 60, were screened for common blood-borne diseases. Grafts were treated in a triple-antibiotic solution at 35°C before preservation at -100°C. Hema-Quebec's vascular graft records were analyzed from 2014 to 2019 inclusively. RESULTS: The average donor age was 35 years old and 78% of donors were men. Overall, 63% of harvested grafts cleared the quality management system. Positive microbial cultures and morphologic defects were the major reasons for graft discard. As such, a total of 60 grafts were delivered between 2016 and 2019 to 8 hospital centers. Moreover, the bank achieved a mean activity increase of 55% per year and Hema-Quebec's homografts were 48% less costly compared with similar homographs from for-profit organizations. CONCLUSIONS: Our findings demonstrate that Hema-Quebec has established a viable cryopreserved vascular tissue bank with steady increase in activity and an acceptable graft discard rates and pricing. Based on our findings, we recommend that efforts should be directed to expand the tissue bank graft distribution outside the province of Quebec.


Assuntos
Antibacterianos/uso terapêutico , Bioprótese , Implante de Prótese Vascular/instrumentação , Prótese Vascular , Vasos Sanguíneos/transplante , Criopreservação , Soluções para Preservação de Órgãos/uso terapêutico , Bancos de Tecidos , Coleta de Tecidos e Órgãos , Adolescente , Adulto , Antibacterianos/efeitos adversos , Vasos Sanguíneos/efeitos dos fármacos , Vasos Sanguíneos/microbiologia , Seleção do Doador , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Soluções para Preservação de Órgãos/efeitos adversos , Avaliação de Programas e Projetos de Saúde , Coleta de Tecidos e Órgãos/efeitos adversos , Adulto Jovem
6.
Transplant Proc ; 52(9): 2781-2785, 2020 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-32741664

RESUMO

Primary nonfunction (PNF) in the early postoperative period following liver transplantation is fatal if not managed appropriately with early retransplantation. Severe early allograft dysfunction can mimic PNF. The identification of treatable causative factors such as sepsis, hepatic artery, or portal vein thrombosis is essential to distinguish it from PNF, and their early management may avoid the need for retransplantation. In this article, we describe a case of sepsis-induced severe liver dysfunction from a contaminated graft perfused with normothermic machine perfusion (NMP), which presented in a manner similar to PNF. The implications of graft contamination are poorly described. To our knowledge, this is the first report of bacterial contamination of a graft that underwent NMP and subsequently caused severe sepsis in the recipient. The conditions created with NMP may be optimal for certain micro-organisms to thrive. The role of the liver in the immune system is complex as it provides an essential barrier to enterically derived portal venous pathogens and produces numerous acute phase proteins that augment the systemic immune response. Additionally, the liver is also known to restrain harmful and excessive systemic immune responses such as those that occur with the sepsis syndrome. The relationship between bacterial graft contamination, sepsis, and graft dysfunction may be multidirectional.


Assuntos
Contaminação de Medicamentos , Transplante de Fígado/efeitos adversos , Soluções para Preservação de Órgãos/efeitos adversos , Preservação de Órgãos/efeitos adversos , Complicações Pós-Operatórias/etiologia , Sepse/etiologia , Feminino , Humanos , Pessoa de Meia-Idade , Perfusão , Doadores de Tecidos
7.
Transplant Proc ; 52(10): 2909-2915, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-32580872

RESUMO

PURPOSE: Routine screening for microbial contamination in organ recovery perfusion transport solution (ORPTS) is by microbiological culture without broth enrichment. Our aim was to examine the clinical utility of broth enrichment of perfusion solution, through use of BACTEC (Becton Dickinson) blood culture media, in preventing wound complications for transplant recipients in comparison with culture without enrichment. METHODS: We prospectively collected samples of ORPTS of 395 kidney (n = 250) or simultaneous pancreas-kidney (SPK, n = 145) donors over a 7-year period. Results of culture with and without broth enrichment (n = 285) using BACTEC blood culture media were examined to compare the sensitivity of BACTEC with non-BACTEC methods. We then conducted a paired analysis of 110 recipients with both BACTEC and non-BACTEC culture organ perfusion media. We examined the rates of wound infection and whether the use of targeted antimicrobials reduced infections in the BACTEC group and recipients with both types of cultures. RESULTS: Of 395 patients with cultures of ORPTS, first, the results of 79 cultures performed using BACTEC media only were compared with 206 non-BACTEC cultures (n = 285). Second, 110 cultures were performed using both methods. For the first part of the study, BACTEC media detected significantly greater microbial growth than non-BACTEC methods (n = 79, 64.6% vs n = 206, 14.6%; P < .001). In the 110 patients with both BACTEC (52.3%) and non-BACTEC cultures (9.9%), there was significantly higher sensitivity of the BACTEC method (P < .001); 68.2% of these patients had antimicrobial cover in the days immediately following transplant sufficient to cover the cultured organism. In the patients with appropriate antimicrobial cover, the rate of recipient wound infection was significantly reduced (P = .003). CONCLUSIONS: Routine screening of ORPTS with BACTEC broth enrichment should always be employed. When paired with antimicrobial prophylaxis, it has the potential to significantly reduce the risk of recipient wound infection.


Assuntos
Contaminação de Medicamentos , Transplante de Rim/efeitos adversos , Infecção dos Ferimentos/prevenção & controle , Adulto , Antibioticoprofilaxia , Estudos de Coortes , Meios de Cultura , Feminino , Humanos , Masculino , Soluções para Preservação de Órgãos/efeitos adversos , Infecção dos Ferimentos/etiologia , Adulto Jovem
8.
Trials ; 21(1): 62, 2020 Jan 10.
Artigo em Inglês | MEDLINE | ID: mdl-31924234

RESUMO

BACKGROUND: Organ preservation before transplantation is still a challenge. Both the University of Wisconsin and Bretschneider's histidine-tryptophan-ketoglutarate (HTK; Custodiol®) solution are standard for liver, kidney and pancreas preservation. Organ preservation with both solutions is comparable; recently, however, Custodiol® solution has been modified to Custodiol-N according to the needs of today. Thus, our study was defined to study its effect in clinical transplantation. METHODS: Patients undergoing kidney transplantation (n = 412) (including approximately 30 combined kidney-pancreas) or liver transplantation (n = 202) receive grafts that have been cold stored in either Custodiol® or Custodiol-N to demonstrate noninferiority of Custodiol-N regarding both graft function and graft injury after transplantation. DISCUSSION: Preclinical data have clearly shown that Custodiol-N is superior to Custodiol® in cold static organ preservation via mechanisms including inhibition of hypoxic cell injury, cold-induced cell injury and avoidance of adverse effects during warm exposure to the solution. Further clinical safety data on Custodiol-N for cardioplegia are available. Thus, this study was designed to compare Custodiol® with Custodiol-N for the first time in a prospective, randomized, single-blinded, multicentre, phase III clinical transplantation trial. TRIAL REGISTRATION: Eudra-CT, 2017-002198-20. Registered on 28 November 2018.


Assuntos
Sobrevivência de Enxerto/efeitos dos fármacos , Transplante de Rim , Transplante de Fígado , Soluções para Preservação de Órgãos/uso terapêutico , Preservação de Órgãos , Transplante de Pâncreas , Coleta de Tecidos e Órgãos , Áustria , Ensaios Clínicos Fase III como Assunto , Glucose/efeitos adversos , Glucose/uso terapêutico , Humanos , Transplante de Rim/efeitos adversos , Transplante de Fígado/efeitos adversos , Manitol/efeitos adversos , Manitol/uso terapêutico , Estudos Multicêntricos como Assunto , Preservação de Órgãos/efeitos adversos , Soluções para Preservação de Órgãos/efeitos adversos , Transplante de Pâncreas/efeitos adversos , Cloreto de Potássio/efeitos adversos , Cloreto de Potássio/uso terapêutico , Procaína/efeitos adversos , Procaína/uso terapêutico , Estudos Prospectivos , Ensaios Clínicos Controlados Aleatórios como Assunto , Método Simples-Cego , Fatores de Tempo , Coleta de Tecidos e Órgãos/efeitos adversos , Resultado do Tratamento
9.
Cardiovasc Ther ; 2019: 9482797, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31772620

RESUMO

INTRODUCTION: Cardiovascular diseases are the number one cause of death globally contributing to 37% of all global deaths. A common complication of cardiovascular disease is heart failure, where, in such cases, the only solution would be to conduct a heart transplant. Every 10 minutes a new patient is added to the transplant waiting list. However, a shortage of human donors and the short window of time available to find a correct match and transplant the donors' heart to the recipient means that numerous challenges are faced by the patient even before the operation could be done, reducing their chances of living even further. METHODS: This review aims to evaluate the application of the Organ Care System (OCSTM) in improving the efficiency of heart storage based on journal articles obtained from PubMed, Elsevier Clinical Key, and Science Direct. RESULTS: Studies have shown that OCS is capable of extending the ischemic time 120 minutes longer than conventional methods without any detrimental effect on the recipient nor donor's safety. Based on the PROTECT I and PROCEED II study, 93% of transplantation recipients using the OCS system passed through the 30-day mortality period. DISCUSSION: OCS is able to prolong the ischemic time of donors' hearts by perfusing the organ at 34°C in a beating state, potentially reducing the detrimental effect of cold storage and providing additional assessment options. Another clear advantage is the implanting surgeon can assess the quality of the donor heart before surgery as well as providing a time safety buffer in unanticipated circumstances that will reduce the mortality risk of transplant recipients.


Assuntos
Seleção do Doador , Transplante de Coração/métodos , Soluções para Preservação de Órgãos/uso terapêutico , Preservação de Órgãos , Perfusão , Doadores de Tecidos/provisão & distribuição , Listas de Espera , Animais , Sobrevivência de Enxerto , Transplante de Coração/efeitos adversos , Transplante de Coração/mortalidade , Humanos , Preservação de Órgãos/efeitos adversos , Preservação de Órgãos/mortalidade , Soluções para Preservação de Órgãos/efeitos adversos , Perfusão/efeitos adversos , Perfusão/mortalidade , Medição de Risco , Fatores de Risco , Fatores de Tempo , Sobrevivência de Tecidos , Resultado do Tratamento
10.
Int J Mol Sci ; 20(13)2019 Jun 27.
Artigo em Inglês | MEDLINE | ID: mdl-31252560

RESUMO

Advanced preservation injury (PI) after intestinal transplantation has deleterious short- and long-term effects and constitutes a major research topic. Logistics and costs favor rodent studies, whereas clinical translation mandates studies in larger animals or using human material. Despite diverging reports, no direct comparison between the development of intestinal PI in rats, pigs, and humans is available. We compared the development of PI in rat, porcine, and human intestines. Intestinal procurement and cold storage (CS) using histidine-tryptophan-ketoglutarate solution was performed in rats, pigs, and humans. Tissue samples were obtained after 8, 14, and 24 h of CS), and PI was assessed morphologically and at the molecular level (cleaved caspase-3, zonula occludens, claudin-3 and 4, tricellulin, occludin, cytokeratin-8) using immunohistochemistry and Western blot. Intestinal PI developed slower in pigs compared to rats and humans. Tissue injury and apoptosis were significantly higher in rats. Tight junction proteins showed quantitative and qualitative changes differing between species. Significant interspecies differences exist between rats, pigs, and humans regarding intestinal PI progression at tissue and molecular levels. These differences should be taken into account both with regards to study design and the interpretation of findings when relating them to the clinical setting.


Assuntos
Mucosa Intestinal/transplante , Preservação de Órgãos/efeitos adversos , Transplantes/normas , Adolescente , Adulto , Animais , Caspase 3/genética , Caspase 3/metabolismo , Conexinas/genética , Conexinas/metabolismo , Criopreservação/métodos , Feminino , Humanos , Mucosa Intestinal/efeitos dos fármacos , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patologia , Masculino , Pessoa de Meia-Idade , Preservação de Órgãos/métodos , Soluções para Preservação de Órgãos/efeitos adversos , Soluções para Preservação de Órgãos/química , Ratos , Ratos Sprague-Dawley , Especificidade da Espécie , Suínos
11.
J Surg Res ; 242: 157-165, 2019 10.
Artigo em Inglês | MEDLINE | ID: mdl-31078900

RESUMO

BACKGROUND: Limited data exist that compare the predominant cardiac preservation solutions (CPSs). MATERIALS AND METHODS: The United Network for Organ Sharing database was retrospectively reviewed from January 1, 2004 to March 31, 2018, for donor hearts. Of 34,614 potential donors, 21,908 remained after applying the exclusion criteria. The CPS analyzed included saline, the University of Wisconsin (UW), cardioplegia, Celsior, and Custodiol. The primary endpoints were recipient survival and posttransplant rejection. Logistic and Cox models were used to quantify survival endpoints. RESULTS: Saline was used as the CPS in 2549 patients (12%), UW in 10,549 (48%), cardioplegia in 1307 (6%), Celsior in 5081 (23%), and Custodiol in 2422 (11%). Donor age ranged from 15 to 68 y (mean = 32.0 y, median = 30.0 y), and 71% were male. Adjusted survival probabilities of recipients whose donor hearts were procured with saline was 96% 30 d, 90% 1 y, UW: 97% 30 d, 92% 1 y, cardioplegia: 95% 30 d, 87% 1 y, Celsior: 96% 30 d, 90% 1 y, and Custodiol: 97% 30 d, 92% 1 y. When these comparisons were adjusted for donor age, sex, ethnicity, ischemic time, recipient age, sex, ethnicity, creatinine, ventricular assist device (VAD), length of stay, region and days on waiting list, cardioplegia solution was demonstrated to have a higher risk of death (30 d, 1 y, overall) and posttransplant rejection versus UW (odds ratio 1.70, P = 0.001; odds ratio 1.63, P < 0.001; hazard ratio 1.22, P < 0.001; hazard ratio 1.21, P < 0.001, respectively). CONCLUSIONS: Cardioplegia solutions for cardiac preservation are associated with a higher mortality in heart transplant recipients.


Assuntos
Soluções Cardioplégicas/efeitos adversos , Rejeição de Enxerto/epidemiologia , Insuficiência Cardíaca/cirurgia , Soluções para Preservação de Órgãos/efeitos adversos , Preservação de Órgãos/efeitos adversos , Adenosina/efeitos adversos , Adolescente , Adulto , Idoso , Aloenxertos/efeitos dos fármacos , Alopurinol/efeitos adversos , Dissacarídeos/efeitos adversos , Eletrólitos/efeitos adversos , Feminino , Seguimentos , Glucose/efeitos adversos , Glutamatos/efeitos adversos , Glutationa/efeitos adversos , Rejeição de Enxerto/etiologia , Rejeição de Enxerto/prevenção & controle , Sobrevivência de Enxerto/efeitos dos fármacos , Coração/efeitos dos fármacos , Insuficiência Cardíaca/mortalidade , Transplante de Coração/efeitos adversos , Histidina/efeitos adversos , Humanos , Insulina/efeitos adversos , Masculino , Manitol/efeitos adversos , Pessoa de Meia-Idade , Preservação de Órgãos/métodos , Cloreto de Potássio/efeitos adversos , Procaína/efeitos adversos , Rafinose/efeitos adversos , Estudos Retrospectivos , Solução Salina/efeitos adversos , Análise de Sobrevida , Resultado do Tratamento , Adulto Jovem
12.
Transplant Proc ; 51(2): 392-395, 2019 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-30879550

RESUMO

INTRODUCTION: Preservation solutions (PS), in which grafts for patients undergoing liver transplantation are stored, represent a medium suitable for microorganism growth and a potential source for transmission of pathogenic germs to the transplant recipients. The aim of the present study was to review the relevant literature for the incidence and predictors of positive microbiological findings in the PS. PATIENTS AND METHODS: We performed a literature review of publications on bacterial and fungal contamination of PS during cold organ storage focusing on its impact on bacteremia and/or nosocomial infection of the recipient. RESULTS: Overall 19 studies were reviewed, published between the years 2000 and 2016, that encompassed a total of 5647 patients. Positive cultures were identified in 1428 patients (25%). The documentation of bacteremia showed a wide deviation with documented ranges between 0% and 69%. Data on the identification of same species or of related nosocomial infections were only sparsely available; same species were found in a rate of 0% to 8%, and nosocomial infections were attributed to them in an incidence of 0% to 19%. CONCLUSIONS: Our study underlines both the limited published data and the contradictory available information on contamination of preservation solution in solid organ transplantation, not allowing for any recommendations. The necessity for prospective, multicentric studies on this topic is mandatory.


Assuntos
Infecção Hospitalar/etiologia , Contaminação de Medicamentos/estatística & dados numéricos , Soluções para Preservação de Órgãos/efeitos adversos , Transplante de Órgãos/efeitos adversos , Adulto , Infecção Hospitalar/epidemiologia , Feminino , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Preservação de Órgãos/efeitos adversos , Preservação de Órgãos/métodos , Estudos Prospectivos , Transplantados
13.
Transplantation ; 102(11): 1870-1877, 2018 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-30130321

RESUMO

BACKGROUND: Both University of Wisconsin (UW) and histidine-tryptophan-ketoglutarate (HTK) solutions are currently used in the Eurotransplant region for preservation of liver allografts. Previous studies on their effect have led to a lot of discussion. This study aims to compare the effect of HTK and UW on graft survival. METHODS: First liver transplantations in recipients 18 years or older from January 1, 2007, until December 31, 2016, were included. Graft survival was compared for livers preserved with HTK and UW at 30 days, 1, 3, and 5 years. Multivariable analysis of risk factors was performed and outcome was adjusted for important confounders. RESULTS: Of all 10 628 first liver transplantations, 8176 (77%) and 2452 (23%) were performed with livers preserved with HTK and UW, respectively. Kaplan-Meier curves showed significant differences in graft survival between HTK and UW at 30 days (89% vs 93%, P=<0.001), 1 year (75% vs 82%, P=<0.001), 3 years (67% vs 72%, P<0.001), and at 5 years (60% vs 67%, P<0.001). No significant differences in outcome were observed in separate analyses of Germany or non-German countries. In multivariable analysis, UW was associated with a decreased risk of graft loss at 30 days (HR 0.772, P=0.002) and at 1 year (0.847 (0.757-0.947). When adjusted for risk factors, no differences in long term outcome could be detected. CONCLUSIONS: Because the use of preservation fluids is clustered geographically, differences in outcome by preservation fluids are strongly affected by regional differences in donor and recipient characteristics. When adjusted for risk factors, no differences in graft survival exist between transplantations performed with livers preserved with either HTK or UW.


Assuntos
Sobrevivência de Enxerto/efeitos dos fármacos , Transplante de Fígado/métodos , Soluções para Preservação de Órgãos/uso terapêutico , Preservação de Órgãos/métodos , Adenosina/efeitos adversos , Adenosina/uso terapêutico , Adulto , Idoso , Alopurinol/efeitos adversos , Alopurinol/uso terapêutico , Europa (Continente) , Feminino , Glucose/efeitos adversos , Glucose/uso terapêutico , Glutationa/efeitos adversos , Glutationa/uso terapêutico , Disparidades em Assistência à Saúde , Humanos , Insulina/efeitos adversos , Insulina/uso terapêutico , Transplante de Fígado/efeitos adversos , Masculino , Manitol/efeitos adversos , Manitol/uso terapêutico , Pessoa de Meia-Idade , Preservação de Órgãos/efeitos adversos , Soluções para Preservação de Órgãos/efeitos adversos , Cloreto de Potássio/efeitos adversos , Cloreto de Potássio/uso terapêutico , Procaína/efeitos adversos , Procaína/uso terapêutico , Rafinose/efeitos adversos , Rafinose/uso terapêutico , Sistema de Registros , Estudos Retrospectivos , Fatores de Risco , Fatores de Tempo , Resultado do Tratamento
14.
Semin Liver Dis ; 38(3): 260-269, 2018 08.
Artigo em Inglês | MEDLINE | ID: mdl-30041278

RESUMO

The discrepancy between the number of patients awaiting liver transplantation and the number of available donors has become a key issue in the transplant setting. Various strategies to cope with the donor shortage problem and to increase the use of suboptimal grafts have been explored. Machine perfusion has been applied ex situ to liver grafts in the effort to improve static cold-storage preservation. If a more extensive application of this technology confirms the preliminary results, machine perfusion will become crucial in increasing the donor pool as well as improving recipients' outcomes. In this review, the authors focused on the evolution of machine perfusion, from the first animal experiences to the latest evidence in humans, highlighting the pros and cons as well as the potential clinical applications of various types of machine.


Assuntos
Transplante de Fígado/métodos , Soluções para Preservação de Órgãos/uso terapêutico , Preservação de Órgãos/métodos , Perfusão/métodos , Traumatismo por Reperfusão/prevenção & controle , Doadores de Tecidos/provisão & distribuição , Animais , Seleção do Doador , Sobrevivência de Enxerto , Humanos , Transplante de Fígado/efeitos adversos , Preservação de Órgãos/efeitos adversos , Preservação de Órgãos/instrumentação , Soluções para Preservação de Órgãos/efeitos adversos , Perfusão/efeitos adversos , Perfusão/instrumentação , Traumatismo por Reperfusão/etiologia , Traumatismo por Reperfusão/patologia , Fatores de Risco , Resultado do Tratamento , Listas de Espera
15.
J Pharmacol Exp Ther ; 366(1): 29-36, 2018 07.
Artigo em Inglês | MEDLINE | ID: mdl-29739826

RESUMO

Intestinal preservation injury (IPI) and the resulting mucosa injury raise several serious challenges early after intestinal transplantation. The current clinical approach using only vascular perfusion allows the shortest preservation period among the abdominal organs. The experimental addition of luminal polyethylene glycol (PEG) solutions has been repeatedly suggested to alleviate preservation injury, improve graft quality, and prolong the preservation time. We investigated whether the molecular mass of PEG in solution influences the development of intestinal preservation injury. Small intestines of Sprague-Dawley rats were perfused with University of Wisconsin solution. Group 1 underwent vascular perfusion only (clinical control), group 2 received additional luminal PEG3350 Da, group 3 received luminal PEG10000 Da, and group 4 received luminal PEG20000 Da (n = 8/group). Tissue samples were obtained after 4, 8, and 14 hours. We studied the tissue damage (Chiu/Park score, Goblet cells, apoptosis, tight junctions), activation of c-Jun NH2-terminal kinase (JNK), and p38-mitogen-activated protein kinase (MAPK), and we performed Ussing chamber assessments. Mucosal morphologic and electrophysiologic parameters were significantly improved in the groups receiving luminal PEG. There was significantly less apoptotic activity in groups 2, 3, and 4. Both MAPKs revealed an activation peak after 4 hours with group 3 showing lesser p38-MAPK activation. PEG 20 kDa interfered with protein immunodetection. The results indicate that luminal solutions of PEG of medium and large molecular mass significantly delay the onset and development of IPI, providing further evidence that luminal interventions may allow for longer cold storage intervals of intestinal grafts.


Assuntos
Intestino Delgado/efeitos dos fármacos , Intestino Delgado/lesões , Soluções para Preservação de Órgãos/efeitos adversos , Polietilenoglicóis/farmacologia , Adenosina/efeitos adversos , Alopurinol/efeitos adversos , Animais , Apoptose/efeitos dos fármacos , Glutationa/efeitos adversos , Insulina/efeitos adversos , Intestino Delgado/metabolismo , Intestino Delgado/patologia , Proteínas Quinases JNK Ativadas por Mitógeno/metabolismo , Masculino , Peso Molecular , Permeabilidade/efeitos dos fármacos , Polietilenoglicóis/química , Rafinose/efeitos adversos , Ratos , Ratos Sprague-Dawley , Junções Íntimas/efeitos dos fármacos , Junções Íntimas/metabolismo , Proteínas Quinases p38 Ativadas por Mitógeno/metabolismo
16.
Gac Med Mex ; 154(2): 217-221, 2018.
Artigo em Espanhol | MEDLINE | ID: mdl-29733059

RESUMO

Introduction: The medium for avulsed teeth storage until their reimplantation is key to the preservation of human periodontal ligament fibroblasts (HPLF). Objective: Our purpose was to compare the cytotoxic effect of milk and isotonic solution, used for the storage of avulsed teeth, on the preservation of HPLF. Method: A subculture of periodontal ligament fibroblasts was carried out with a density of 1:2 (3 ×105 cells/mL) and was incubated for 48 hours. The cells were divided in two groups, which were placed either in milk or isotonic solution for 24 hours at 5% CO2, 37 ºC and 95% humidity. The number of viable cells was determined with a colorimetric fast assay by the reduction of MTT and mitochondrial activity. Data were processed with the Shapiro-Wilk normality test, Student's t-test and paired Student's t-test (with significance set at 0.05). Results: The cells exposed to milk for 24 hours showed statistically significant cytotoxicity at concentrations of 0.09, 0.39, 0.78, 1.56, 3.125, 6.25 and 50%. HPLFs exposed to isotonic solution showed no significant reduction in the number of cells at concentrations of 25 and 50%. Conclusion: Isotonic solution appears to be better for HPLF 24-hour storage in comparison with whole milk.


Introducción: El medio de almacenamiento de los dientes avulsionados hasta su reimplante es vital para conservar los fibroblastos del ligamento periodontal humano (HPLF). Objetivo: Comparar el efecto citotóxico para conservar los HPLF de la leche y la solución isotónica para almacenamiento de dientes avulsionados. Método: Se realizó subcultivo de fibroblastos del ligamento periodontal con una densidad de 1:2 (3 × 105 células/mL), que fueron incubados por 48 horas. Se integraron dos grupos de células, que se colocaron en leche y solución isotónica durante 24 horas a 5 % de CO2, a 37°C y 95 % de humedad. El número de células viables fue determinado por colorimetría rápida por reducción de MTT y actividad mitocondrial. Los datos fueron sometidos a pruebas de normalidad de Shapiro-Wilk, t de Student y t de Student pareada (significación de 0.05). Resultados: Las células expuestas a la leche por 24 horas mostraron citotoxicidad estadísticamente significativa a concentraciones de 0.09, 0.39, 0.78, 1.56, 3.125, 6.25 y 50 %. Los HPLF expuestos a solución isotónica no mostraron reducción significativa del número de células a concentraciones de 25 y 50 %. Conclusión: La solución isotónica parece mejor para el almacenamiento de HPLF en 24 horas, comparada con la leche entera.


Assuntos
Citotoxinas/efeitos adversos , Fibroblastos/efeitos dos fármacos , Soluções Isotônicas/efeitos adversos , Leite/efeitos adversos , Soluções para Preservação de Órgãos/efeitos adversos , Ligamento Periodontal/citologia , Avulsão Dentária , Animais , Células Cultivadas , Humanos
17.
World J Gastroenterol ; 24(16): 1812-1824, 2018 Apr 28.
Artigo em Inglês | MEDLINE | ID: mdl-29713134

RESUMO

AIM: To compare the effects of the four most commonly used preservation solutions on the outcome of liver transplantations. METHODS: A systematic literature search was performed using MEDLINE, Scopus, EMBASE and the Cochrane Library databases up to January 31st, 2017. The inclusion criteria were comparative, randomized controlled trials (RCTs) for deceased donor liver (DDL) allografts with adult and pediatric donors using the gold standard University of Wisconsin (UW) solution or histidine-tryptophan-ketoglutarate (HTK), Celsior (CS) and Institut Georges Lopez (IGL-1) solutions. Fifteen RCTs (1830 livers) were included; the primary outcomes were primary non-function (PNF) and one-year post-transplant graft survival (OGS-1). RESULTS: All trials were homogenous with respect to donor and recipient characteristics. There was no statistical difference in the incidence of PNF with the use of UW, HTK, CS and IGL-1 (RR = 0.02, 95%CI: 0.01-0.03, P = 0.356). Comparing OGS-1 also failed to reveal any difference between UW, HTK, CS and IGL-1 (RR = 0.80, 95%CI: 0.80-0.80, P = 0.369). Two trials demonstrated higher PNF levels for UW in comparison with the HTK group, and individual studies described higher rates of biliary complications where HTK and CS were used compared to the UW and IGL-1 solutions. However, the meta-analysis of the data did not prove a statistically significant difference: the UW, CS, HTK and IGL-1 solutions were associated with nearly equivalent outcomes. CONCLUSION: Alternative solutions for UW yield the same degree of safety and effectiveness for the preservation of DDLs, but further well-designed clinical trials are warranted.


Assuntos
Transplante de Fígado/métodos , Soluções para Preservação de Órgãos/uso terapêutico , Preservação de Órgãos/métodos , Adenosina/uso terapêutico , Alopurinol/uso terapêutico , Dissacarídeos/uso terapêutico , Eletrólitos/uso terapêutico , Glucose/uso terapêutico , Glutamatos/uso terapêutico , Glutationa/uso terapêutico , Sobrevivência de Enxerto , Histidina/uso terapêutico , Humanos , Insulina/uso terapêutico , Transplante de Fígado/efeitos adversos , Manitol/uso terapêutico , Razão de Chances , Preservação de Órgãos/efeitos adversos , Soluções para Preservação de Órgãos/efeitos adversos , Cloreto de Potássio/uso terapêutico , Disfunção Primária do Enxerto/etiologia , Procaína/uso terapêutico , Rafinose/uso terapêutico , Ensaios Clínicos Controlados Aleatórios como Assunto , Fatores de Risco , Fatores de Tempo , Resultado do Tratamento
18.
Transplant Proc ; 50(2): 539-542, 2018 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-29579846

RESUMO

INTRODUCTION: Ischemia reperfusion injury (IRI) is the main cause of early allograft dysfunction (EAD) and subsequent primary allograft failure (PAF). OBJECTIVES: The purpose of this study is to compare IRI, EAD, and PAF in liver transplantation in a cohort of patients perfused with histidine-tryptophan-ketoglutarate (HTK) solution and University of Wisconsin (UW) solution versus HTK alone. METHODS: A randomized trial was performed to compare outcomes in liver recipients who underwent transplantation surgery in the University Regional Hospital of Malaga, Spain. Forty patients were randomized to two groups. Primary endpoints included IRI, EAD, PAF, re-intervention, acute cellular rejection, retransplantation, arterial complications, and biliary complications at postoperative day 90. RESULTS: Postoperative glutamic oxaloacetic transaminase (1869.15 ± 1559.75 UI/L vs. 953.15 ± 777.27 UI/L; P = .004) and glutamic pyruvic transaminase (1333.60 ± 1115.49 U/L vs. 721.70 ± 725.02 U/L; P = .023) were significantly higher in patients perfused with HTK alone. A clear tendency was observed in recipients perfused with HTK alone to present moderate to severe IRI (7 patients in the HTK + UW solution group vs. 15 patients in the HTK-alone solution group; P = .06), EAD (0 patients in the HTK + UW solution group vs. 0 patients in the HTK-alone solution group; P = .76), and PAF (3 patients in the HTK + UW solution group vs. 8 patients in the HTK-alone solution group; P = .15). CONCLUSIONS: Initial perfusion with HTK solution followed by UW solution in liver transplantation improves early liver function as compared to perfusion with HTK alone.


Assuntos
Transplante de Fígado/métodos , Soluções para Preservação de Órgãos/administração & dosagem , Perfusão/métodos , Adenosina/administração & dosagem , Adenosina/efeitos adversos , Adulto , Alanina Transaminase/sangue , Alopurinol/administração & dosagem , Alopurinol/efeitos adversos , Aspartato Aminotransferases/sangue , Estudos de Coortes , Quimioterapia Combinada , Feminino , Glucose/administração & dosagem , Glucose/efeitos adversos , Glutationa/administração & dosagem , Glutationa/efeitos adversos , Rejeição de Enxerto/induzido quimicamente , Humanos , Insulina/administração & dosagem , Insulina/efeitos adversos , Fígado , Masculino , Manitol/administração & dosagem , Manitol/efeitos adversos , Pessoa de Meia-Idade , Soluções para Preservação de Órgãos/efeitos adversos , Perfusão/efeitos adversos , Período Pós-Operatório , Cloreto de Potássio/administração & dosagem , Cloreto de Potássio/efeitos adversos , Procaína/administração & dosagem , Procaína/efeitos adversos , Rafinose/administração & dosagem , Rafinose/efeitos adversos , Reoperação , Traumatismo por Reperfusão/induzido quimicamente , Espanha , Resultado do Tratamento
19.
Prog Urol ; 28(6): 322-328, 2018 May.
Artigo em Inglês | MEDLINE | ID: mdl-29395835

RESUMO

INTRODUCTION: Bacterial colonization of preservative solutions (PS) remains poorly described in renal transplantation. We investigated the bacterial colonization of the PS and its influence on graft pyelonephritis within one year from the renal transplantation. PATIENTS AND METHODS: We cultured 2 samples of PS from 424 patients who underwent a renal transplantation. The follow-up period was one year. An acute graft pyelonephritis was defined as a positive bacteriological urine analysis, with temperature higher than 38.5°C or graft pain. RESULTS: In total, 424 samples of PS were tested and 195 were positive for colonization (46%). Forty-five patients developed an acute graft pyelonephritis during the follow-up period (10.6%), of which, 21 (46.7%) showed a colonization of their PS. Twenty-four had no colonization (53.3%). This difference was not significant (P=0.697). DISCUSSION: Our data suggest that the bacterial colonization of PS samples does not seem to increase the risk of acute graft pyelonephritis in renal transplant recipients. LEVEL OF EVIDENCE: -3.


Assuntos
Transplante de Rim/efeitos adversos , Rim/microbiologia , Soluções para Preservação de Órgãos/efeitos adversos , Complicações Pós-Operatórias/microbiologia , Pielonefrite/microbiologia , Infecções Urinárias/microbiologia , Doença Aguda , Adulto , Idoso , Feminino , Seguimentos , Rejeição de Enxerto/epidemiologia , Rejeição de Enxerto/microbiologia , Humanos , Rim/patologia , Masculino , Pessoa de Meia-Idade , Soluções para Preservação de Órgãos/normas , Complicações Pós-Operatórias/epidemiologia , Pielonefrite/epidemiologia , Estudos Retrospectivos , Fatores de Risco , Infecções Urinárias/epidemiologia
20.
Transplant Rev (Orlando) ; 32(2): 85-91, 2018 04.
Artigo em Inglês | MEDLINE | ID: mdl-29275111

RESUMO

Contamination of the preservation fluid (PF) used for donated organs is a potential source of post-transplant infection. However, the information on this issue is scarce. We therefore conducted a systematic review and meta-analysis to assess the incidence of culture-positive PF and its impact on solid organ transplant (SOT) recipients. Seventeen studies were identified and included. The overall incidence of culture-positive PF was 37% (95% CI: 27% to 49%), and the incidence of PF-related infections among SOT recipients with PF cultures that grew pathogenic microorganisms was 10% (95% CI: 7% to 15%). There were differences in the rates of infections due to pathogenic microorganisms between SOT recipients who received pre-emptive treatment and those who did not, but without statistical significance. The mortality rate among SOT recipients with PF-related infection was 35% (95% CI: 21% to 53%). In conclusion, although contamination of the PF of donated organs is frequent, the incidence of PF-related infection is relatively low. A closely clinical and microbiologic monitoring of the SOT recipient in case of culture-positive PF, regardless of the type of microorganism isolated might be do in order to establish a prompt diagnosis of PF-related infection.


Assuntos
Contaminação de Medicamentos , Soluções para Preservação de Órgãos/efeitos adversos , Transplante de Órgãos/efeitos adversos , Complicações Pós-Operatórias/microbiologia , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...